Safety and Immunogenicity of Convacell in Healthy Volunteers

Phase 2, randomised, double-blind trial of Convacell in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Saint Petersburg Scientific Research Institute of Vaccines and Serums. Primary endpoints: Incidence of actively detected local and systemic Adverse Events (Stage I) at 21 days, Incidence of actively detected local and systemic Adverse Events (Stage II) at 21 days and 1 more. Started Jul 2021; status: completed.